• Je něco špatně v tomto záznamu ?

The placebo and nocebo effects in functional urology

H. Mostafaei, S. Jilch, GL. Carlin, K. Mori, F. Quhal, B. Pradere, E. Laukhtina, VM. Schuettfort, A. Aydh, R. Sari Motlagh, CG. Roehrborn, SF. Shariat, S. Hajebrahimi

. 2022 ; 19 (3) : 171-189. [pub] 20211223

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019320
E-zdroje Online Plný text

NLK ProQuest Central od 2009-04-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2009-04-01 do Před 1 rokem

Odkazy

PubMed 34949831
DOI 10.1038/s41585-021-00545-2
Knihovny.cz E-zdroje

A placebo is an inert substance normally used in clinical trials for comparison with an active substance. However, a placebo has been shown to have an effect on its own; commonly known as the placebo effect. A placebo is an essential component in the design of conclusive clinical trials but has itself become the focus of intense research. The placebo effect is partly the result of positive expectations of the recipient on the state of health. Conversely, a nocebo effect is when negative expectations from a substance lead to poor treatment outcomes and/or adverse events. Randomized controlled trials in functional urology have demonstrated the importance of the placebo and nocebo effects across different diseases such as overactive bladder, urinary incontinence, lower urinary tract symptoms and interstitial cystitis/painful bladder syndrome, as well as male and female sexual dysfunction. Understanding the true nature of the placebo-nocebo complex and the scope of its effect in functional urology could help urologists to maximize the positive effects of this phenomenon while minimizing its potentially negative effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019320
003      
CZ-PrNML
005      
20220804135548.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41585-021-00545-2 $2 doi
035    __
$a (PubMed)34949831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran $1 https://orcid.org/0000000155961771
245    14
$a The placebo and nocebo effects in functional urology / $c H. Mostafaei, S. Jilch, GL. Carlin, K. Mori, F. Quhal, B. Pradere, E. Laukhtina, VM. Schuettfort, A. Aydh, R. Sari Motlagh, CG. Roehrborn, SF. Shariat, S. Hajebrahimi
520    9_
$a A placebo is an inert substance normally used in clinical trials for comparison with an active substance. However, a placebo has been shown to have an effect on its own; commonly known as the placebo effect. A placebo is an essential component in the design of conclusive clinical trials but has itself become the focus of intense research. The placebo effect is partly the result of positive expectations of the recipient on the state of health. Conversely, a nocebo effect is when negative expectations from a substance lead to poor treatment outcomes and/or adverse events. Randomized controlled trials in functional urology have demonstrated the importance of the placebo and nocebo effects across different diseases such as overactive bladder, urinary incontinence, lower urinary tract symptoms and interstitial cystitis/painful bladder syndrome, as well as male and female sexual dysfunction. Understanding the true nature of the placebo-nocebo complex and the scope of its effect in functional urology could help urologists to maximize the positive effects of this phenomenon while minimizing its potentially negative effects.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a symptomy dolních močových cest $7 D059411
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nocebo efekt $7 D064786
650    _2
$a placebo efekt $7 D015990
650    _2
$a výsledek terapie $7 D016896
650    12
$a urologie $7 D014572
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Jilch, Sandra $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Carlin, Greta Lisa $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000277688558
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $1 https://orcid.org/0000000289530272
700    1_
$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Aydh, Abdulmajeed $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u King Faisal Medical City, Abha, Saudi Arabia $1 https://orcid.org/0000000160786816
700    1_
$a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
700    1_
$a Roehrborn, Claus G $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology research foundation, Arnhem, Netherlands. shahrokh.shariat@meduniwien.ac.at $1 https://orcid.org/0000000266276179
700    1_
$a Hajebrahimi, Sakineh $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran $1 https://orcid.org/0000000314947097
773    0_
$w MED00184385 $t Nature reviews. Urology $x 1759-4820 $g Roč. 19, č. 3 (2022), s. 171-189
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34949831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135542 $b ABA008
999    __
$a ok $b bmc $g 1822780 $s 1170563
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 19 $c 3 $d 171-189 $e 20211223 $i 1759-4820 $m Nature reviews. Urology $n Nat Rev Urol $x MED00184385
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace